pulmonary embolism
Cardiovascular · 2013–2013
Every decision here pre-dates the consumer comments facility, so no input would be recorded either way.
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| rivaroxaban Treatment of acute symptomatic pulmonary embolism (PE) and prevention of recurrent venous thromboembolism (VTE). | Mar 2013 | Recommended with restriction | no section in document |
What the PBS pays
$128M in government benefit over 2024–25, across 2,696,588 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| rivaroxaban | $128M |
Appraised elsewhere
NICE, in England and Wales, has appraised 1 technology for this condition, recommending 1 . A different committee, a different population and a different price: this is what has been looked at there, not a verdict on what happened here.
| Technology | Appraisal | Outcome | Date |
|---|---|---|---|
| apixabanApixaban for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism | TA341 | recommended | 2015-06 |
Registered, not subsidised
Medicines on the ARTG for this condition with no PBAC record at all. Registration and subsidy are separate decisions: a medicine can be legally available in Australia and never have been put to the committee.
| Medicine | On the ARTG since | Registrations |
|---|---|---|
| alteplaseACTILYSE CATHFLO alteplase (rch) 2 mg powder for injection vial | 1991 | 4 |
The ARTG export holds current registrations only, so the year is the earliest entry still on the register rather than a first-registration date. The condition here comes from the registered label, which is usually broader than the population a sponsor asks to have subsidised.
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 0 of 0 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.